Quantification of the Therapeutic Antibody Ocrelizumab in Mouse Brain Interstitial Fluid Using Cerebral Open Flow Microperfusion and Simultaneous Monitoring of the Blood–Brain Barrier Integrity

The increasing relevance of improved therapeutic monoclonal antibodies (mAbs) to treat neurodegenerative diseases has strengthened the need to reliably measure their brain pharmacokinetic (PK) profiles. The aim of this study was, therefore, to absolutely quantify the therapeutic antibody ocrelizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Altendorfer-Kroath, Thomas, Hummer, Joanna, Kollmann, Denise, Boulgaropoulos, Beate, Raml, Reingard, Birngruber, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383368/
https://www.ncbi.nlm.nih.gov/pubmed/37514066
http://dx.doi.org/10.3390/pharmaceutics15071880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383368/
https://www.ncbi.nlm.nih.gov/pubmed/37514066
http://dx.doi.org/10.3390/pharmaceutics15071880

Ejemplares similares